Click Here for 5% Off Your First Aladdin Purchase!

Ublituximab (anti-CD20) - Primary antibody, specific to MS4A1, >95%, high purity, Human IgG1, Antibody of CD20 (membrane-spanning 4-domains; subfamily A; member 1)

  • Azide Free
  • Carrier Free
  • ExactAb™
  • Low Endotoxin
  • Recombinant
  • Validated
  • ≥95%(SDS-PAGE&SEC)
  • Lot by Lot
Features and benefits
  • Short Overview:

    Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Species reactivity(Reacts with): Human
  • Isotype: Human IgG1
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
Ab175689
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175689-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$59.90
Ab175689-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$279.90
Ab175689-5mg
5mg
In stock
$739.90
Ab175689-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,189.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product NameUblituximab (anti-CD20) - Primary antibody, specific to MS4A1, >95%, high purity, Human IgG1
SynonymsAPY antibody; ATOPY antibody; B lymphocyte antigen CD20 antibody; B Lymphocyte Cell Surface Antigen B1 antibody; B-lymphocyte antigen CD20 antibody; B-lymphocyte cell-surface antigen B1 antibody; B-lymphocyte surface antigen B1 antibody; B1 antibody; Bp 3
Specifications & PurityExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
SpecificityMS4A1
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeBINDING AGENT
Mechanism of actionAntibody of CD20 (membrane-spanning 4-domains; subfamily A; member 1)
Product Description

Ublituximab (anti-CD20) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab (anti-CD20) has anticancer effects.

Product Properties

IsotypeHuman IgG1
Light Chain Typekappa
SDS-PAGE26.3 kDa (Light Chain) & 51.1 kDa (Heavy Chain), under reducing conditions; 191.4 kDa, under non-reducing conditions.
Purification MethodProtein A purified
Purity>95%
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS1174014-05-1

Images

Ublituximab (anti-CD20) (Ab175689) - ELISA
Immobilized Human CD20 VLP at 2.0 μg/mL can bind Ublituximab (anti-CD20) (Ab175689) with the EC₅₀ of 11.41 ng/mL.

Ublituximab (anti-CD20) (Ab175689) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD20 (red) with Ublituximab (anti-CD20) (Ab175689). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Ublituximab (anti-CD20) (Ab175689) - Flow Cytometry
Flow Cytometry analysis of Ramos cells labelling CD20 (red) with Ublituximab (anti-CD20) (Ab175689). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Ublituximab (anti-CD20) (Ab175689) - SEC
The purity of Ublituximab (anti-CD20) (Ab175689) is more than 95% verified by HPLC.

Ublituximab (anti-CD20) (Ab175689) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD20 with Ublituximab (anti-CD20) (Ab175689) conjugated with biotin (right panel) compared with Human IgG (Ab170213) conjugated with biotin - Isotype Control (left panel) and detected with SA-PE (rp156250).

Ublituximab (anti-CD20) (Ab175689) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD20 (red) with Ublituximab (anti-CD20) (Ab175689) conjugated with biotin and detected with SA-PE (rp156250). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.

Associated Targets

MS4A1 Tclin B-lymphocyte antigen CD20 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0404184Certificate of AnalysisApr 07, 2024 Ab175689
ZJ24F0404183Certificate of AnalysisApr 07, 2024 Ab175689
ZJ24F0404182Certificate of AnalysisApr 07, 2024 Ab175689

Related Documents

References

1. de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, Jorieux S, Bihoreau N, Behrens CK, Béliard R et al..  (2008)  Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16..  Br J Haematol,  140  (6): (635-43).  [PMID:18302712]
2. Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, Davi F, Debré P, Prost JF, Teillaud JL et al..  (2011)  Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies..  Leukemia,  25  (1): (101-9).  [PMID:20975664]
3. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E et al..  (2010)  CD20 deficiency in humans results in impaired T cell-independent antibody responses..  J Clin Invest,  120  (1): (214-22).  [PMID:20038800]
4. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM.  (2004)  Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma..  Clin Cancer Res,  10  (8): (2868-78).  [PMID:15102696]
5. Li B, Xu L, Pi C, Yin Y, Xie K, Tao F, Li R, Gu H, Fang J.  (2017)  CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy..  Oncoimmunology,  (1): (e1380142).  [PMID:29296544]
6. Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E et al..  (2015)  Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies..  Sci Transl Med,  (287): (287ra70).  [PMID:25972002]
7. Tedder, T F TF, Streuli, M M, Schlossman, S F SF and Saito, H H..  (1988)  Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes..  Proceedings of the National Academy of Sciences of the United States of America,      [PMID:2448768]
8. Einfeld, D A DA, Brown, J P JP, Valentine, M A MA, Clark, E A EA and Ledbetter, J A JA..  (1988)  Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains..  The EMBO journal,      [PMID:2456210]
9. Tedder, T F TF, Klejman, G G, Schlossman, S F SF and Saito, H H..  (1989)  Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1)..  Journal of immunology (Baltimore, Md. : 1950),    (1):   [PMID:2466899]
10. Stamenkovic, I I and Seed, B B..  (1988)  Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein..  The Journal of experimental medicine,    (1):   [PMID:3260267]
11. Tedder, T F TF, Boyd, A W AW, Freedman, A S AS, Nadler, L M LM and Schlossman, S F SF..  (1985)  The B cell surface molecule B1 is functionally linked with B cell activation and differentiation..  Journal of immunology (Baltimore, Md. : 1950),      [PMID:3925015]
12. Bubien, J K JK, Zhou, L J LJ, Bell, P D PD, Frizzell, R A RA and Tedder, T F TF..  (1993)  Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes..  The Journal of cell biology,      [PMID:7684739]
13. and Goldenberg, D M DM..  ()  The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy..  Critical reviews in oncology/hematology,      [PMID:11418316]
14. and Dillman, R O RO..  ()  Monoclonal antibody therapy for lymphoma: an update..  Cancer practice,      [PMID:11879282]
15. .  (2003)  Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab..  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,      [PMID:12899647]
16. Li, Haidong H, Ayer, Linda M LM, Lytton, Jonathan J and Deans, Julie P JP..  (2003)  Store-operated cation entry mediated by CD20 in membrane rafts..  The Journal of biological chemistry,    (24):   [PMID:12920111]
17. Du, Jiamu J and 8 more authors..  (2008)  Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide..  Molecular immunology,      [PMID:18346788]
18. Dörner, Thomas T and Burmester, Gerd R GR..  (2008)  New approaches of B-cell-directed therapy: beyond rituximab..  Current opinion in rheumatology,      [PMID:18388516]
19. Polyak, Maria J MJ, Li, Haidong H, Shariat, Neda N and Deans, Julie P JP..  (2008)  CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins..  The Journal of biological chemistry,    (4):   [PMID:18474602]
20. Niederfellner, Gerhard G and 16 more authors..  (2011)  Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies..  Blood,    (14):   [PMID:21444918]
21. Ivaldi, Corinne C and 6 more authors..  (2012)  Proteomic analysis of S-acylated proteins in human B cells reveals palmitoylation of the immune regulators CD20 and CD23..  PloS one,      [PMID:22615937]
22. Phuah, Jiayao J and 10 more authors..  (2016)  Effects of B Cell Depletion on Early Mycobacterium tuberculosis Infection in Cynomolgus Macaques..  Infection and immunity,      [PMID:26883591]
23. Hayashi, Kazumi and 6 more authors..  (2016)  Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation..  Cancer science,      [PMID:26920337]

Solution Calculators